Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism

British Journal of Pharmacology

Volumn 119, Issue 1, 1996, Pages 174-182

  Ruiz, Fernando ^a   Fournié Zaluski, Marie Claude ^a   Roques, Bernard P ^a   Maldonado, Rafael ^a  

^a Laboratoire de Pharmacochimie   (France)

Author keywords

CCK(B) receptors; Clonidine; Endogenous enkephalins; Methadone; PD 134,308; RB 101; Spontaneous morphine withdrawal

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; CHOLECYSTOKININ B RECEPTOR; CLONIDINE; ENKEPHALIN; METHADONE; MORPHINE; N [3 [(2 AMINO 4 METHYLTHIO)BUTYLDITHIO] 2 BENZYLPROPIONYL]PHENYLALANINE BENZYL ESTER; NALOXONE;

ABSTINENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CATABOLISM; CONTROLLED STUDY; DRUG EFFICACY; INTRAPERITONEAL DRUG ADMINISTRATION; MAINTENANCE THERAPY; MALE; METABOLISM; MORPHINE ADDICTION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; WITHDRAWAL SYNDROME;

EID: 0029838588     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15691.x     Document Type: Article

References (64)

1. AGHAJANIAN, G.K. (1978). Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response to clonidine. Nature, 276, 186-187.
2. I dopamine receptor stimulation. Eur. J. Pharmacol., 216, 157-166.
3. BOURGOIN, S., LE BARS, D., ARTAUD, F., CLOT, A.M., BOUBOUTOU, R., FOURNIÉ-ZALUSKI, M.C., ROQUES, B.P., HAMON, M. & CESSELIN, F. (1986). Effects of kelatorphan and other peptidase inhibitors on the in vitro and in vivo release of met-enkephalin-like material from the rat spinal cord. J. Pharmacol. Exp. Ther., 238, 360-366.
4. BUTCHER, S.P., VARR, A., KELLY, J.S. & DOCKRAY, G.J. (1989). In vivo studies on the enhancement of cholecystokinin release in the striatum by dopamine depletion. Brain Res., 505, 119-122.
5. CESSELIN, F., BOURGOIN, S., ARTAUD, F. & HAMON, M. (1984). Basic and regulatory mechanism of in vitro release of Metenkephalin from the dorsal zone of the rat spinal cord. J. Neurochem., 43, 763-773.
6. CONWAY, E.L. & JARROT, B. (1980). Clonidine distribution in the rat: Temporal relationship between tissue levels and blood pressure response. Br. J. Pharmacol., 71, 473-478.
7. COWAN, A., ZHU, X.Z., MOSBERG, H.I., OMNAAS, J.R. & PORRECA, F. (1988). Direct dependence studies in rats with agents selective for different types of opioid receptor. J. Pharmacol. Exp. Ther., 246, 950-955.
8. CRAIN, S.M. & SHEN, K.F. (1990). Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol. Sci., 11, 77-81.
9. DING, X.Z. & BAYER, B.M. (1993). Increases of CCK mRNA and peptide in different brain areas following acute and chronic administration of morphine. Brain Res., 625, 139-144.
10. DOURISH, C.T., HAWLEY, D. & IVERSEN, S.D. (1988). Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. Eur. J. Pharmacol., 147, 469-472.
11. B antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in rat. Eur. J. Pharmacol., 175, 35-44.
12. DZOLJIC, M.R., BOKSZANSKA, A., KORENHOF, A.M., KAPLAN, C.D., DZOLJIC, M., RUPREHT, J., ZIJLSTRA, F.J., BRINKMAN, E.C.A. & CAPPENDIJK, S.T.L. (1992). The effects of orally active enkephalinase inhibitors on morphine withdrawal syndrome. Neuroreport, 3, 637-640.
13. DZOLJIC, M.R., RADEMAKER, B., POEL-HEISTERKAMP, A.L., UKPONMWAN, O.E. & HAFFMANS, J. (1986). Enkephalinase inhibition suppresses naloxone-induced jumping in morphine-dependent mice. Arch. Int. Pharmacodyn., 283, 222-228.
14. EL-KADI, A.O.S. & SHARIF, S.I. (1994). The influence of various experimental conditions on the expression of naloxone-induced withdrawal symptoms in mice. Gen. Pharmacol., 25, 1505-1510.
15. ESPOSITO, E., KRUSZEWSKA, A., OSSOWSKA, G. & SAMANIN, R. (1987). Noradrenergic and behavioural effects of naloxone injected in the locus coeruleus of morphine-dependent rats and their control by clonidine. Psychopharmacology, 93, 393-396.
16. FARIS, P.L., KOMISARUK, B.R., WATKINS, L.R. & MAYER, D.J. (1983). Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science, 219, 310-312.
17. FOURNIÉ-ZALUSKI, M.C., CHAILLET, P., BOUBOUTOU, R., COULAUD, A., CHÉROT, P., WAKSMAN, G., COSTENTIN, J. & ROQUES, B.P. (1984). Analgesic effects of kelatorphan, a new highly potent inhibitor of multiple enkephalin degrading enzymes. Eur. J. Pharmacol., 102, 525-528.
18. FOURNIÉ-ZALUSKI, M.C., CORIC, P., TURCAUD, S., LUCAS, E., NOBLE, F., MALDONADO, R. & ROQUES, B.P. (1992). "Mixed inhibitor-Prodrug" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes. J. Med. Chem., 35, 2473-2481.
19. GONZALVEZ, M.L., MILANES, M.V., MARTINEZ-PINERO, M.G., MARIN, M.T. & VARGAS, M.L. (1994). Effects of intracerebroventricular clonidine on the hypothalamic noradrenaline and plasma corticosterone levels of opiate naive rats and after naloxone-induced withdrawal. Brain Res., 647, 199-203.
20. GUITART, X., HAYWARD, M., NISENBAUM, L.K., BEITNER-JOHN-SON, D.B., HAYCOCK. J.W. & NESTLER, E.J (1990). Identification of MARPP-58, a morphine- and cyclic AMP-regulated phosphoprotein of 58 kDa, as tyrosine hydroxylase: evidence for regulation of its expression by chronic morphine in the rat locus coeruleus. J. Neurosci., 10, 2649-2659.
21. HAFFMANS, J. & DZOLJIC, M.R. (1987). Inhibition of enkephalinase activity attenuates naloxone-precipitated withdrawal symptoms. Gen. Pharmacol., 18, 103-105.
22. HAGINO, Y., OKUWA, M. & MOROJI, T (1991). Effects of ceruletide and haloperidol on the hypothalamo-pituitary β-endorphine system and brain β-endorphine contents in the rat: with special reference to the effects of ceruletide in chronically haloperidol treated rats. Neuropeptides, 18, 1-14.
23. HAMBROOK, J.M., MORGAN, B.A., RANCE, M.J. & SMITH, C.F.C. (1976). Mode of deactivation of the enkephalins by rat and human plasma and rat brain homogenates. Nature, 26, 782-783.
24. HARRIS, G.C. & ASTON-JONES, G. (1993). Beta-adrenergic antagonists attenuate somatic and aversive signs of opiate withdrawal. Neuropsychopharmacology, 9, 303-311.
25. HUGHES, J., BODEN, P., COSTALL, B., DOMENEY, A., KELLY, E., HORWELL, D.C., HUNTER, J.C., PINNOCK, R.D. & WOODRUFF, G.N. (1990). Development of a class selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. Nat. Acad. Sci. U.S.A., 87, 6728-6732.
26. KALIVAS, P.W., NEMEROFF, C.B. & PRANGE, A.J. JR. (1984). Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing. Neuroscience, 11, 919-930.
27. LIVINGSTON, S.J., SEWELL, R.D.E., RODNEY, K.F. & SMITH, H.J. (1988). Amelioration of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphan. Psychopharmacology, 94, 540-544.
28. MAKMAN, M.H., DVORKIN, B. & CRAIN, S.M. (1988). Modulation of adenylate cyclase activity of mouse spinal cord-ganglion explants by opioids, serotonin and pertussis toxin. Brain Res., 445, 303-313.
29. MALDONADO, R., DAUGÉ, V., CALLEBERT, J., VILLETE, J.M., FOURNIÉ-ZALUSKI, M.C., FEGER, J. & ROQUES, B.P. (1989). Comparison of selective and complete inhibitors of enkephalin-degrading enzymes on morphine withdrawal syndrome. Eur. J. Pharmacol., 165, 199-207.
30. B antagonist strongly potentiates antinociception mediated by endogenous enkephalins. Neuroreport, 7, 947-950.
31. MALDONADO, R., NEGUS, S. & KOOB, G. F. (1992). Precipitation of morphine withdrawal syndrome in rats by administration of mu-delta- and kappa-selective opioid antagonists. Neuropharmacology, 31, 1231-1241.
32. B receptors, on morphine-dependent rats. Pharmacol. Biochem. Behav., 48, 363-369.
33. B antagonist PD-134,308. Br. J. Pharmacol., 114, 1031-1039.
34. MALFROY, B., SWERTS, J.P., GUYON, A., ROQUES, B.P. & SCHWARTZ, J.C. (1978). High-affinity enkephalin-degrading peptidase in mouse brain and its enhanced activity following morphine. Nature, 276, 523-526.
35. MILLINGTON, W.R., MUELLER, G.P. & LAVIGNE, G.J. (1992). Cholecystokinin type A and B receptor antagonists produce opposing effects on cholecystokinin-stimulated beta-endorphin secretion from the rat pituitary. J. Pharmacol. Exp. Ther., 261, 454-461.
36. MORAN, T.H., ROBINSON, P.H., GOLDRICH, M.S. & MCHUGH, P.R. (1986). Two brain cholecystokinin receptors: implication for behavioral actions. Brain Res., 362, 175-179.
37. NESTLER, E.J. (1992). Molecular mechanisms of drug addiction. J. Neurosci., 12, 2439-2450.
38. NESTLER, E.J., ERDOS, J.J., TERWILLIGER, R., DUMAS, R.S & TALLMAN, J.F. (1989). Regulation of G-proteins by chronic morphine treatment in the rat locus coeruleus. Brain Res., 476, 230-239.
39. NESTLER, E.J. & TALLMAN, J.F (1988). Chronic morphine treatment increases cyclic AMP-dependent protein kinase activity in the rat locus coeruleus. Mol. Pharmacol., 33, 127-132.
40. NOBLE, F., DERRIEN, M. & ROQUES, B.P. (1993). Modulation of opioid antinociception by CCK at the supraspinal level: Evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br. J. Pharmacol., 109, 1064-1070.
41. NOBLE, F., SOLEIHAC, J.M., SOROCA-LUCAS, E., TURCAUD, S., FOURNIE-ZALUSKI, M.C. & ROQUES, B.P (1992). Inhibition of enkephalin metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. J. Pharmacol. Exp. Ther., 261, 181-190.
42. NOBLE, F., SMADJA, C. & ROQUES, B.P. (1994). Role of endogenous cholecystokinin in the facilitation of mu-mediated antinociception by delta-opioid agonists. J. Pharmacol. Exp. Ther., 271, 1127-1134.
43. O'BRIEN, C.P. (1993). Opioid Addiction. In Opioids, Handbook of Experimental Pharmacology, vol 104/II. ed. Herz, A., Akil, H. & Simon, E.J. pp. 803-823. Berlin Heidelberg: Springer-Verlag.
44. PANERAI, A.E., ROVATI, L.C., COCCO, E., SACERDOTE, P. & MANTEGAZZA, P. (1987). Dissociation of tolerance and dependence to morphine: a possible role for cholecystokinin. Brain Res., 410, 52-60.
45. POURNAGHASH, S. & RILEY, A (1991). Failure of cholecystokinin to precipitate withdrawal in morphine-treated rats. Pharmacol. Biochem. Behav., 38, 479-484.
46. ROQUES, B.P. & NOBLE, F. (1995). Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addition. In Discovery of Novel Opioid Medications, NIDA Res Monograph series, vol 147. ed. Rapaka, R.S., & Sorer, H. pp. 14-145. National Institute on Drug Abuse, Rockville.
47. ROQUES, B.P., NOBLE, F., DAUGÉ, V., FOURNIÉ-ZALUSKI, M.C. & BEAUMONT, A. (1993). Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharmacol. Rev., 45, 97-146.
48. RUIZ-GAYO, M., BAAMONDE, A., TURCAUD, S., FOURNIÉ-ZALUSKI, M.C. & ROQUES, B.P. (1992). In vivo occupation of mouse brain opioid receptors by endogenous enkephalins: blockade of enkephalin degrading enzymes by RB 101 inhibits [3H] diprenorphine binding. Brain Res., 571, 306-312.
49. SHEARMAN, G.T., LAL, H. & URSILLO, R.C. (1980). Effectiveness of lofexidine in blocking morphine-withdrawal signs in the rat. Pharmacol. Biochem. Behav., 12, 573-575.
50. B receptors in the modulation of endogenous enkephalin anti-depressant-like effects. Psychopharmacology, 120, 400-408.
51. STEWART, J., DE WIT, H. & EIKELBOOM, R (1984). Role of unconditioned and conditioned drug effects in the self administration of opiates and stimulants. Psychol. Rev., 91, 251-268.
52. TERWILLIGER, R., BEITNER-JOHNSON, D., SEVARINO, K.A., GRAIN, S.M. & NESTLER, E.J. (1991). A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res., 548, 100-110.
53. TSENG, T.F., LOH, H.H. & WEI, E.T. (1975). Effects of clonidine on morphine withdrawal signs in the rat. Eur. J. Pharmacol., 30, 93 - 99.
54. TYE, N.C. & IVERSEN, S.D. (1975). Some behavioural signs of morphine withdrawal blocked by conditional stimuli. Nature, 255, 416-418.
55. B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J. Pharmacol. Exp. Ther., 270, 77-88.
56. VAN DER LAAN, J.W & DE GROOT, G. (1988). Changes in locomotor-activity patterns as a measure of spontaneous morphine withdrawal: no effect of clonidine. Drug Alcohol Depend., 22, 133-140.
57. VAN DER LAAN, J.W., VAN'T LAND, C.J., LOEBER, J.G. & DE GROOT, G. (1991). Validation of spontaneous morphine withdrawal symptoms in rats. Arch. Int. Pharmacodyn., 311, 32-45.
58. VAUGHT, J.L. (1988). Substance P antagonists and analgesia: a review of the hypothesis. Life. Sci., 43, 1419-1431.
59. WAKSMAN, G., BOUBOUTOU, R., DEVIN, J., BOURGOIN, S., CESSELIN, F., HAMON, M., FOURNIÉ-ZALUSKI, M.C. & ROQUES, B,P. (1985). In vitro and in vivo effects of kelatorphan on enkephalin metabolism in rodent brain. Eur. J. Pharmacol., 117, 233-243.
60. WANG, X.J. & HAN, J.S. (1990). Modification by cholecystokinin octapeptide of the binding of μ-, δ, and κ-opioid receptors. J. Neurochem., 55, 1379-1382.
61. WISE, R.A. & BOZARTH, M.A. (1987). A psychomotor stimulant theory of addiction. Psychol. Rev., 94, 469-492.
62. XU, X.J., WIESENFELD-HALLIN, Z., HUGHES, J., NORWELL, D.C. & HÖKFEL, T. (1992). CI988, a selective antagonist of cholecystokinin B receptors, prevents morphine tolerance in the rat. Br. J. Pharmacol., 105, 591-596.
63. YAKSH, T.L., SABBE, M.B., LUCAS, D., MJANGER, E. & CHIPKIN, R.E. (1991). Effects of [N-(L-(1-carboxy-2-phenyl)ethyl]-L-phenylalanyl-β-alanine (SCH 32615), a neutral endopeptidase (enkephalinase) inhibitor, on levels of enkephalin, encrypted enkephalins and substance P in cerebrospinal fluid and plasma of primates. J. Pharmacol. Exp. Ther., 256, 1033-1041.
64. ZHOU, Y., SUN, Y.H., ZHANG, Z.W. & HAN, J.S. (1992). Accelerated expression of cholecystokinin gene in the brain of rats rendered tolerant to morphine. Neuroreport, 3, 1121-1123.